ReviewFrontiers in medicine2017
The Role of Cytokines in the Fibrotic Responses in Crohn's Disease.
Review in Frontiers in medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 48 citations in OpenAlex.
- A biomechanical model of inflammation-driven colon hypertrophy and dysmotility: Application to Gulf War Illness.Journal of the mechanical behavior of biomedical materials · 2026Article
- Mechanostimulatory Cues Determine Intestinal Fibroblast Fate and Profibrotic Remodeling in a Physiodynamic Human Gut-on-a-Chip.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Inhibition of CDK8 rescues impaired ischemic fracture healing.NPJ Regenerative medicine · 2026Article
- Cellular senescence in Crohn's disease: a double-edged sword in intestinal fibrosis.Frontiers in immunology · 2026Review
- Ustekinumab enhances intestinal stenosis resolution by modulating fibrotic pathways in crohn's disease: a retrospective single-center study with translational analysis.BMC gastroenterology · 2025Article
- Adiponectin deficiency prevents chronic colitis-associated colonic fibrosis via inhibiting CXCL13 production.Journal of advanced research · 2025Article
- Restoring Prostacyclin/PGI2-PTGIR signaling alleviates intestinal fibrosis in Crohn's disease via fibroblast-specific YAP/TAZ inhibition.Journal of Crohn's & colitis · 2025Article
- Idiopathic Intestinal Smooth Muscle Hyperplasia in a French Bulldog: Clinical, Imaging, Capsule Endoscopy, and Histopathological Findings.Animals : an open access journal from MDPI · 2025Article
- Immunohistochemistry Analysis in Inflammatory Bowel Disease-Should We Bring to Light Interleukin-10?Biomedicines · 2025Article
- Review
- Injectable Microparticle-containing hydrogel with controlled release of bioactive molecules for facial rejuvenation.Materials today. Bio · 2024Article
- Anti-fibrotics in inflammatory bowel diseases: Challenges and successes.Advances in pharmacology (San Diego, Calif.) · 2024Review
- Ustekinumab affects myofibroblast metabolism to alleviate intestinal fibrosis by targeting KDELC1 in Crohn's disease through multi-machine learning combined with single-cell sequencing analysis.Frontiers in medicine · 2024Article
- Multifunctional PDO Thread Coated with Mg(OH)Pharmaceutics · 2023Article
- Dual function of fungi-derived cytokines in inflammatory bowel diseases: protection or inflammation.Gastroenterology report · 2023Review
- The Gut Microbiota Metabolite Succinate Promotes Adipose Tissue Browning in Crohn's Disease.Journal of Crohn's & colitis · 2022Article
- Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease.Clinical science (London, England : 1979) · 2022Article
- Perindopril/Ambrosin Combination Mitigates Dextran Sulfate Sodium-Induced Colitis in Mice: Crosstalk between Toll-Like Receptor 4, the Pro-Inflammatory Pathways, and SIRT1/PPAR-γ Signaling.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Development of antifibrotic therapy for stricturing Crohn's disease: lessons from randomized trials in other fibrotic diseases.Physiological reviews · 2022Review
- Potential Role of Epithelial Endoplasmic Reticulum Stress and Anterior Gradient Protein 2 Homologue in Crohn's Disease Fibrosis.Journal of Crohn's & colitis · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crohn's disease is an idiopathic disorder of the gut thought to be caused by a combination of environmental and genetic factors in susceptible individuals. It is characterized by chronic transmural inflammation of the terminal ileum and colon, with typical transmural lesions. Complications, including fibrosis, mean that between 40 and 70% of patients require surgery in the first 10 years after diagnosis. Presently, there is no evidence that the current therapies which dampen inflammation modulate or reverse intestinal fibrosis. In this review, we focus on cytokines that may lead to fibrosis and stenosis and the contribution of experimental models for understanding and treatment of gut fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.